The Therapeutic Effect of Beta-3 Agonist and Anti-muscarinic Agent on Overactive Bladder Among Sjogren's Syndrome Patient
Latest Information Update: 07 Aug 2023
At a glance
- Drugs Mirabegron (Primary) ; Oxybutynin; Solifenacin; Tolterodine
- Indications Overactive bladder; Sjogren's syndrome
- Focus Therapeutic Use
- 08 Aug 2021 Status changed from not yet recruiting to recruiting.
- 29 Jul 2021 Planned End Date changed from 15 Jun 2022 to 15 Aug 2022.
- 29 Jul 2021 Planned primary completion date changed from 15 Jun 2022 to 15 Aug 2022.